MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 4, 2005; DOI: 10.1124/mol.104.008292


0026-895X/05/6704-1214-1220$20.00
Mol Pharmacol 67:1214-1220, 2005

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.008292v1
67/4/1214    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Collins, A.
Right arrow Articles by Larson, M. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Collins, A.
Right arrow Articles by Larson, M. K.
Original Article

Differential Sensitivity of Kir2 Inward-Rectifier Potassium Channels to a Mitochondrial Uncoupler: Identification of a Regulatory Site

Anthony Collins, Haoran Wang, and Maureen K. Larson

Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon

Received October 14, 2004; accepted January 3, 2005

Abstract

The aim of this study was to gain insight into the mechanism by which members of the Kir2 subfamily are differentially sensitive to agents that inhibit mitochondrial function by identifying responsible site(s) in Kir2 proteins. Kir2 channels were expressed in Xenopus laevis oocytes and assayed by two-electrode voltage clamp and patch clamp. Incubation of oocytes in carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP), a mitochondrial uncoupler, inhibited Kir2.2 and Kir2.3, but not Kir2.1. Replacement of the first 44 amino acids of Kir2.2 the or of first 19 Kir2.3 with the first 45 of Kir2.1 did not affect the sensitivity of the channels to FCCP. In contrast, a larger substitution of Kir2.1 N-terminal sequence (1-78) into Kir2.2 or Kir2.3 produced channels that were resistant to FCCP. Sequence alignment between residues 46 and 78 (Kir2.1 numbering) revealed four residues that are the same in Kir2.2 and Kir2.3 but different in Kir2.1. Each of these four residues in the resistant chimera was converted back to the Kir2.2/Kir2.3 amino acid. Three of the mutants (D51N, I59A, and G65S) were not sensitive to FCCP, but the H53Q mutant was sensitive. Kir2.1-H53A and Kir2.1-H53E were also sensitive. In contrast, Kir2.1-H53R and Kir2.1-H53K were recovered during resistant. Kir2.2 and Kir2.3 currents perfusion of inside-out patches from FCCP-treated oocytes. FCCP was without effect on Kir2.2 and Kir2.3 when applied directly to inside-out patches. Together, these results suggest inhibition of Kir2.2 and Kir2.3 by a ligand that bears a positive charge and is produced by an intracellular action of FCCP.


Mitochondrial dysfunction is increasingly recognized as an important aspect of the pathophysiology of several neurological and cardiovascular disorders, including Alzheimer's disease (Baloyannis et al., 2004Go), Parkinson's disease (Fiskum et al., 2003Go), heart failure (Marin-Garcia et al., 2001Go), myocardial and cerebral ischemia (Sims and Anderson, 2002Go; Sadek et al., 2003Go), and, potentially, epilepsy (Patel, 2002Go). Alteration of electrical excitability is central to many of these diseases, leading to either neuronal excitotoxicity or cardiac arrhythmia (Doble, 1999Go; Janse, 2004Go). Inward-rectifier K+ channels play a special role in controlling membrane excitability, so the inhibition of their activity would be expected to have a proexcitotoxic or proarrhythmic effect. Indeed, the reduction of cardiac inward-rectifier activity seen in heart failure (Beuckelmann et al., 1993Go; Kaab et al., 1996Go; Lodge and Normandin, 1997Go; Han et al., 2001Go) contributes to the increased risk of arrhythmogenic triggered activity arising from afterdepolarizations (Pogwizd et al., 2001Go).

We investigated previously the possibility that inward-rectifier K+ channels provide a link between mitochondrial dysfunction and membrane excitability and found that members of the Kir2 subfamily are differentially sensitive to agents that inhibit mitochondrial function (Collins and Larson, 2002Go). The aim of this study was to gain some insight into the nature of the mechanism by identifying the site(s) in the Kir2 proteins that are responsible for this differential sensitivity.

The membrane topology and subunit stoichiometry originally proposed by Ho et al. (1993Go) and Kubo et al. (1993Go) for inward-rectifier K+ channels is now well accepted, especially in light of the recent determination of the crystal structure of an inward-rectifier-type channel protein from a prokaryote (Kuo et al., 2003Go). Thus, inward-rectifier channels are composed of four subunits, each of which has two transmembrane {alpha}-helices (M1 and M2) and an extracellular reentrant helix loop (H5) that forms the selectivity filter. The amino and carboxyl termini are both intracellular. Here, we show that the sensitivity of Kir2 channels to a mitochondrial uncoupler depends on the charge of a specific residue in the N-terminal domain and provide evidence for the role of a ligand that bears a positive charge.

Materials and Methods

Subcloning, Mutagenesis, and In Vitro Transcription. Complementary DNAs encoding Kir2.1 (IRK1) (Kubo et al., 1993Go), Kir2.2 (MB-IRK2) (Takahashi et al., 1994Go), and Kir2.3 (MB-IRK3) (Kurachi and Takahashi, 1996Go) were subcloned into the Xenopus laevis expression vector pGEMHE (Liman et al., 1992Go). Point mutants and novel restriction sites were introduced by the QuikChange method (Stratagene, La Jolla, CA). Chimeras were constructed by first introducing a unique silent restriction site into the Kir2.1 coding sequence and at the equivalent site in the Kir2.2 or Kir2.3 coding sequence. These plasmids were then digested with the appropriate restriction enzyme and BamHI (5' to the coding sequence) or NheI (3' to the coding sequence). The resulting DNA fragments were separated by agarose gel electrophoresis and purified with the MiniElute Gel Extraction Kit (QIAGEN, Valencia, CA). Fragments were then ligated using the Fast-Link kit (Epicenter Technologies, Madison, WI) to form plasmids containing the novel chimeras. All chimeras and point mutants were confirmed by DNA sequencing (Central Services Laboratory, Center for Gene Research and Biotechnology, Oregon State University, Corvallis, OR). Plasmids were linearized with NheI, and cRNA was transcribed in vitro with T7 RNA polymerase (mMessage mMachine; Ambion, Austin, TX). RNA yield and integrity were assessed by agarose-ethidium bromide gel electrophoresis.

Oocyte Isolation. Stage V to VI oocytes were surgically removed from X. laevis frogs (Nasco, Fort Atkinson, WI) under anesthesia (0.03% benzocaine for 10-15 min) and incubated with 1 mg/ml collagenase (type CLS3; Worthington Biochemicals, Freehold, NJ) for 2 h at 22°C in 96 mM NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM HEPES, pH 7.4, with agitation to remove connective tissue. Oocytes were then washed several times with 96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, and 5 mM HEPES, pH 7.4 (ND-96) and stored in the same solution at 18°C. Both solutions also contained 100 µg/ml streptomycin and 60 µg/ml ampicillin. Oocytes were injected up to 24 h later (Nanoliter; World Precision Instruments, Sarasota, FL) with 50 nl of nuclease-free water containing amounts of RNA that gave similar expression levels.

Two-Electrode Voltage Clamp. Inward-rectifier currents were recorded 1 to 2 days after injection using a TEC-03 amplifier (NPI Electronic GmbH, Tamm, Germany) controlled by Pulse 8.4 software (Heka, Southboro, MA) via an ITC-16 computer interface (InstruTECH Corporation, Port Washington, NY). Currents were filtered at 500 Hz and digitized at 1 kHz. Data were analyzed using Pulse 8.4 and Prism 3.02 (GraphPad Software Inc., San Diego, CA). Microelectrode pipettes were prepared from thin-walled, 1.5-mm outer diameter borosilicate glass capillaries (TW150F-3; World Precision Instruments) on a microprocessor-controlled puller (PUL-100; World Precision Instruments) and had resistances of 0.5 to 1.5 M{Omega} when filled with 3 M KCl. Oocytes were placed in a 100-µl volume recording chamber that was continuously perfused at a rate of approximately 1.2 ml/min with 90K solution (90 mM KCl/KOH, 3 mM MgCl2, and 5 mM HEPES, pH 7.4).

Patch Clamp. Inward-rectifier currents were recorded in giant cell-attached and inside-out patches from X. laevis oocytes (Hilgemann, 1995Go) 2 to 4 days after injection with Kir2 cRNA. The patch-clamp amplifier was an Axopatch 200B (Axon Instruments Inc., Union City, CA). Currents were filtered at 1 kHz, and data were acquired at 5 kHz with a Digidata 1320A computer interface and pClamp 8 software (Axon Instruments). Data were analyzed using pClamp 8 and Prism 3.02. Patch pipettes had inner tip diameters of 20 to 25 µm. The composition of recording solutions is given in the figure legends.

Materials. Restriction enzymes were purchased from MBI Fermentas (Hanover, MD) or New England Biolabs (Beverly, MA). Carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP; MP Biomedicals, Irvine, CA) was dissolved in dimethyl sulfoxide to 100 mM. This stock solution was diluted into experimental solutions as indicated in the figure legends. ATP (dipotassium salt) was purchased from MP Biomedicals. Phosphatidylinositol 4,5-bisphosphate (PIP2) was purchased from EMD Biosciences (San Diego, CA) and prepared according to the methods of Rohacs et al. (2002Go). PIP2 was dispersed in water at a concentration of 1 mM and then sonicated for 25 min on ice in a Sonic 100W (Fisher Scientific International, Hampton, NH) at 50% power. After sonication, the sample was divided into 33-µl aliquots and stored at -80°C. The suspension was injected directly into the oocyte. Thawed aliquots were used on the same day, and unused material was discarded.

Results

Fig. 1A shows the effect of FCCP, a mitochondrial uncoupler (Guerrieri et al., 1976Go), on three different members of the Kir2 inward-rectifier K+ channel subfamily. Current-voltage relationships were obtained by two-electrode voltage clamp after incubation for 90 min in 10 µM FCCP or in control conditions. The figure demonstrates that Kir2.2 and Kir2.3 were inhibited by FCCP, whereas Kir2.1 was not.



View larger version (48K):
[in this window]
[in a new window]
 
Fig. 1. Effect of FCCP on Kir2 channels and chimeras expressed in X. laevis oocytes. Inward-rectifier K+ currents were recorded by two-electrode voltage clamp after incubation in ND-96 (control) or for 90 min in ND-96 with 10 µM FCCP. A, current-voltage relationships recorded from oocytes expressing Kir2.1 (squares), Kir2.2 (triangles), or Kir2.3 (circles) in control conditions (open symbols) or after FCCP treatment (filled symbols). Data were normalized to the current recorded at a membrane potential of -50 mV. Inward current is presented as negative. Data are mean ± S.E.M., n = 6. Error bars smaller than the size of the symbol are not shown. B, schematic representations of wild-type and chimeric Kir2 channel sequences (left) and their sensitivity to FCCP (right). N, amino terminal of the sequence; C, carboxyl terminal. M1, M2, and H5 represent the first and second transmembrane {alpha} helices and the re-entrant pore helix-loop, respectively. White and black correspond to Kir2.1 sequence, dark gray and diagonal correspond to Kir2.2 sequence, and light gray and cross-hatch correspond to Kir2.3 sequence. Right, bars represent inward-rectifier current recorded at -50 mV membrane potential in control conditions ({square}) or after FCCP treatment ({blacksquare}). Bar length is mean current (n = 6); error bars represent S.E.M. The calibration line represents 5 µA. ***, p < 0.001 for control versus FCCP by t test.

 

Figure 1B shows the effect of FCCP on chimeric channels in which part of the N-terminal domain of Kir2.2 or Kir2.3 was replaced with the equivalent sequence from Kir2.1. The horizontal bars at the right of the figure represent the K+ current recorded at a membrane potential of -50 mV after control ({square}) or FCCP treatment ({blacksquare}). Comparison of these data for 1-2chm1 and 1-3chm1 with the data for wild-type Kir2.1, Kir2.2, and Kir2.3 shows that replacement of the first 44 amino acids of Kir2.2 or the first 19 amino acids of Kir2.3 with the first 45 amino acids of Kir2.1 did not affect the sensitivity of the channels to FCCP. In contrast, a larger substitution of Kir2.1 N-terminal sequence (78 amino acid residues) into Kir2.2 (1-2chm2) or Kir2.3 (1-3chm2) produced channels that were resistant to FCCP (compare 1-2chm2 and 1-3chm2 ± FCCP data with Kir2.1 ± FCCP data). Therefore, replacement of most of the N-terminal domain of Kir2.2 or Kir2.3 with Kir2.1 sequence eliminated the sensitivity to FCCP.

The data presented in Fig. 1B suggested that sequence differences between residues 46 and 78 (Kir2.1 numbering) affect the sensitivity of Kir2 channels to FCCP. Examination of the sequence alignment for this segment revealed four residues that are the same in Kir2.2 and Kir2.3 but different in Kir2.1 (shown in boldface type in the top part of Fig. 2). Point mutations were made in 1-3chm2 so that one of these four residues was converted back to the Kir2.2/Kir2.3 amino acid. These four mutants are represented schematically in Fig. 2. The bars at the right of the figure represent the K+ current recorded at -50 mV in control conditions ({square}) or after FCCP treatment ({blacksquare}). Three of the mutants (D51N, I59A, and G65S) were not sensitive to FCCP. In contrast, the H53Q mutant, in which the histidine residue at position 53 (Kir2.1 numbering) was changed to glutamine, was inhibited by FCCP.



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 2. Effect of point mutations on FCCP sensitivity. Top, alignment of Kir2.1, Kir2.2, and Kir2.3 sequences from residue 46 to 78 (Kir2.1 numbering). Positions of point mutations are shown in boldface. Bottom left, schematic representations of point mutants in the 1-3chm2 chimera, which has Kir2.1 sequence from residues 1 to 78 and Kir2.3 sequence thereafter. Bottom right, data obtained and represented as in Fig. 1.

 

The results shown in Fig. 2 suggested that glutamine at position 53 (Kir2.1 numbering) is a specific requirement for sensitivity of Kir2 channels to FCCP or that histidine specifically produces resistance to FCCP. Figure 3 shows that glutamine does not have a specific role in conferring sensitivity to FCCP because the mutation of histidine 53 in Kir2.1 to alanine (H53A) or glutamate (H53E) also produced FCCP-sensitive channels. In contrast, Kir2.1 mutants in which histidine 53 was changed to arginine (H53R) or lysine (H53K) retained their resistance to FCCP (Fig. 3).



View larger version (17K):
[in this window]
[in a new window]
 
Fig. 3. Sensitivity of Kir2.1 to FCCP is influenced by the charge on residue 53. Residue 53 in Kir2.1 was mutated to glutamine (H53Q), alanine (H53A), arginine (H53R), lysine (H53K), or glutamate (H53E). Mutant channels were expressed in X. laevis oocytes and inward-rectifier current was recorded by two-electrode voltage clamp after incubation in ND-96 (control; {square}) or for 90 min in ND-96 with 10 µM FCCP ({blacksquare}). Data are currents recorded at -50 mV, normalized to the mean control current for each mutant. **, p < 0.01; ***, p < 0.001 by t test (n = 6).

 

Figure 4 shows that Kir2.2 and Kir2.3 could recover from inhibition by FCCP. These experiments were conducted in oocytes that were expressing Kir2.2 or Kir2.3 and were incubated in 10 µM FCCP for 1 h. The inward-rectifier current was recorded by patch clamp. The inverted triangles represent the current recorded at -50 mV in the cell-attached patch configuration at the beginning of the experiment. The broken lines represent the period of time during which the patches of membrane were excised into the inside-out configuration. The excision of intact "giant" patches (Hilgemann, 1995Go) takes longer than the excision of conventional patches. After excision, the inside-out patches were perfused with FVPP solution (40 mM KCl, 75 mM potassium gluconate, 5 mM potassium fluoride, 0.1 mM sodium vanadate, 10 mM potassium pyrophosphate, 1 mM EGTA, 0.2 mM ADP, 10 mM HEPES, 10 mM glucose, and 0.1 spermine, pH 7.4) (see Fig. 4 legend). As can be seen in the figure, Kir2.2 and Kir2.3 currents (solid lines) increased with time of perfusion. The leak current (data not shown) was stable and negligible throughout.



View larger version (11K):
[in this window]
[in a new window]
 
Fig. 4. Recovery of Kir2.2 and Kir2.3 in inside-out patches. X. laevis oocytes expressing Kir2.2 or Kir2.3 were treated with 10 µM FCCP in ND-96 for 1 h, and then inward-rectifier currents were recorded by patch clamp. The same FVPP-type solution was used in the recording dish and in patch pipettes and for perfusing inside-out patches: 40 mM KCl, 75 mM potassium gluconate, 5 mM KF, 0.1 mM NaVO3, 10 mM potassium pyrophosphate, 1 mM EGTA, 0.1 mM spermine, and 10 mM HEPES, pH 7.4. Traces represent inward currents recorded at -50 mV membrane potential. Leak current was monitored at 50 mV and was stable and negligible throughout. {blacktriangledown}, cell-attached configuration. The broken lines represent the periods during which membrane patches were excised into the inside-out configuration. Data were not acquired during these periods. The solid lines are currents recorded during perfusion of inside-out patches with FVPP. The voltage error because of series resistance was approximately 2 mV at the end of the Kir2.2 experiment (electrode resistance, 830 k{Omega}) and approximately 0.5 mV at the end of the Kir2.3 experiment (electrode resistance, 780 k{Omega}).

 

FCCP did not inhibit Kir2.2 and Kir2.3 when applied directly to the cytoplasmic surface of membrane patches, as shown in Fig. 5. The figure shows superimposed current traces recorded in inside-out patches from X. laevis oocytes expressing Kir2.2 or Kir2.3 during perfusion with FVPP solution (control) or 10 µM FCCP in FVPP.



View larger version (14K):
[in this window]
[in a new window]
 
Fig. 5. No direct inhibition of FCCP on Kir2.2 or Kir2.3. Inward-rectifier currents were recorded by patch clamp in X. laevis oocytes expressing Kir2.2 or Kir2.3. The same FVPP-type solution was used in the recording dish and in patch pipettes, and for perfusing inside-out patches: 40 mM KCl, 75 mM potassium gluconate, 5 mM KF, 0.1 mM NaVO3, 10 mM sodium pyrophosphate, 1 mM EGTA, 10 mM glucose, 0.1 mM spermine, and 10 mM PIPES, pH 7.4. Traces represent currents recorded in inside-out patches from oocytes expressing Kir2.2 (A) and Kir2.3 (B) while applying the voltage-clamp protocol shown in C before (control) and during the application of 10 µM FCCP. The slight increase in inward current was seen in control conditions and was probably not caused by FCCP. The voltage error caused by series resistance was approximately 1 mV in A (electrode resistance, 800 k{Omega}) and approximately 5 mV in B (electrode resistance, 640 k{Omega}).

 

Figure 6 shows that the inhibition of Kir2.2 and Kir2.3 by FCCP was not attenuated by ATP or PIP2. In this experiment, oocytes were preinjected with 50 nl of water, 1 mM PIP2, or 50 mM ATP before incubation in FCCP. Comparison of the open and closed bars shows that the inhibition of Kir2.2 and Kir2.3 by FCCP after PIP2 or ATP preinjection was equivalent to the inhibition in control conditions.



View larger version (14K):
[in this window]
[in a new window]
 
Fig. 6. No effect of ATP or PIP on the inhibition of Kir2.2 and Kir2.3 by 2FCCP. X. laevis oocytes expressing Kir2.2 (A) or Kir2.3 (B) were injected with 50 nl of water (columns 1-4), 1 mM PIP2 (columns 5 and 6), or 50 mM ATP (columns 7 and 8), incubated in ND-96 for 60 min (ATP) or 30 to 60 min (PIP2), then incubated for a further 90 min in ND-96 (control; {square}) or ND-96 with 10 µM FCCP ({blacksquare}). Inward-rectifier currents were then recorded in 90K by two-electrode voltage clamp. Data are currents recorded at -50 mV, normalized to the mean control current. ***, p < 0.001 by t test (n = 5-10).

 

According to sequence alignments, the equivalent position to histidine 53 in Kir2.1 is position 52 in Kir2.2 and position 27 in Kir2.3. To investigate whether a histidine at this position is sufficient to confer resistance to FCCP, glutamine-to-histidine mutations were made at position 52 in Kir2.2 (Q52H) and position 27 in Kir2.3 (Q27H). Figure 7 shows that these mutants were inhibited by FCCP (compare open and filled bars).



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 7. A histidine residue at position 53 (Kir2.1 numbering) is not sufficient to make Kir2.2 or Kir2.3 resistant to FCCP. The glutamine residue at the position equivalent to Kir2.1 residue 53 was mutated to histidine in Kir2.2 (position 52) and Kir2.3 (position 27). These constructs were expressed in X. laevis oocytes, which were then incubated for 90 min in ND-96 with 10 µM FCCP ({blacksquare}) or ND-96 (control; {square}). Inward-rectifier currents were then recorded in 90K by two-electrode voltage clamp. Data are currents recorded at -50 mV normalized to the mean control current. **, p < 0.01; ***, p < 0.001 by t test (n = 6).

 

Discussion

The data presented here show that the resistance to FCCP of Kir2.1 in comparison to Kir2.2 and Kir2.3 was eliminated by changing the histidine residue at position 53 to a neutral or negatively charged residue. In contrast, resistance to FCCP was retained when the histidine was changed to arginine or lysine. Thus, the presence of a positively charged residue at position 53 is required for resistance to FCCP rather than a requirement for histidine per se.

FCCP uncouples oxidative phosphorylation from electron transport by acting as a proton ionophore in the inner mitochondrial membrane (Heytler and Prichard, 1962Go; Guerrieri et al., 1976Go). This action depolarizes the mitochondria (Aronis et al., 2002Go), thereby inhibiting ATP production (Luo et al., 1997Go). Inward-rectifier K+ channels are known to be activated by PIP2 (Hilgemann and Ball, 1996Go; Huang et al., 1998Go; Rohacs et al., 1999Go), and neutralization of histidine 53 was found to decrease Kir2.1's affinity for PIP2 (Lopes et al., 2002Go). This led us to hypothesize a mechanism in which FCCP depletes ATP, leading in turn to a depletion of PIP2 because of continued lipid phosphatase activity in the face of decreased phosphorylation of inositol phospholipids. Depletion of PIP2 would then lead to inward-rectifier K+-channel inhibition. However, this hypothesis is not supported by our data, because Kir2.2 and Kir2.3 currents recovered from inhibition by FCCP when inside-out patches were perfused with a solution that did not contain ATP (Fig. 4). ATP is required for the regeneration of PIP2 in inside-out patches (Hilgemann and Ball, 1996Go; Huang et al., 1998Go). Furthermore, Kir2.1 and Kir2.2 have similar affinities for PIP2 (Du et al., 2004Go), and preinjection of oocytes with PIP2 or ATP did not attenuate the inhibition of Kir2.2 or Kir2.3 by FCCP (Fig. 6).

A possible explanation for the observed influence of the side-chain charge of residue 53 on the sensitivity of the channel to FCCP is that this charge alters the affinity of a binding site for an inhibitory ligand. Such a mechanism predicts that the inhibitory effect of FCCP will be reversed if the putative ligand is washed away from the intracellular surface of the membrane. The data presented in Fig. 4 support such a mechanism, because perfusion of inside-out membrane patches from FCCP-treated oocytes resulted in the recovery of Kir2.2 and Kir2.3 currents.

Residues other than residue 53 (Kir2.1 numbering) would inevitably be involved in forming the putative regulatory site. Such residues could be variant between Kir2.1 and Kir2.2/Kir2.3 because mutation of the glutamine residue at the position equivalent to Kir2.1 His53 (residue 52 in Kir2.2, residue 27 in Kir2.3) to histidine was insufficient to convert Kir2.2 and Kir2.3 to FCCP-resistant channels (Fig. 7). On the other hand, FCCP could exert its effect via a second binding site on Kir2.2 and Kir2.3. Further mutagenesis studies will address this issue.

From the results presented here, we speculate that mitochondrial dysfunction in heart failure (Marin-Garcia et al., 2001Go) produces an inward-rectifier K+-channel inhibitor that is responsible for reducing the cardiac inward-rectifier current (Beuckelmann et al., 1993Go; Kaab et al., 1996Go; Lodge and Normandin, 1997Go; Han et al., 2001Go), thereby contributing to an increased risk of arrhythmia (Pogwizd et al., 2001Go). Furthermore, we speculate that the inhibitor bears a positive charge, because the presence of a positive charge in or near the binding site would be expected to decrease the affinity of the channel for the positively charged moiety of the inhibitory ligand. As reported previously, the inhibitory effect of FCCP cannot be entirely accounted for by intracellular acidification (Collins and Larson, 2005Go).

Gene knockout studies indicate that Kir2.1 is an essential component of the cardiac inward-rectifier current (Zaritsky et al., 2001Go). As shown here and previously (Collins and Larson, 2002Go), Kir2.1 is relatively insensitive to mitochondrial inhibitors. Therefore, if the cardiac inward-rectifier channels were all Kir2.1 homomultimers, it would be less likely that the inhibition of inward-rectifier activity in heart failure was caused by mitochondrial dysfunction. However, evidence in the literature suggests that a significant proportion of cardiac inward rectifiers are Kir2.1-Kir2.2 or Kir2.1-Kir2.3 heteromultimers (Zaritsky et al., 2001Go; Preisig Muller et al., 2002Go; Zobel et al., 2003Go), which are sensitive to FCCP (Collins and Larson, 2005Go). Kir2.1, Kir2.2, and Kir2.3 are all transcribed in human heart (Wang et al., 1998Go), so it is likely that a significant proportion of inward-rectifier K+ channels in human cardiac myocytes are Kir2.1-Kir2.2 and/or Kir2.1-Kir2.3 heteromultimers that may be sensitive to mitochondrial dysfunction.

Several neurological disorders are characterized by neuronal excitotoxicity and mitochondrial dysfunction (Doble, 1999Go; Patel, 2002Go; Sims and Anderson, 2002Go; Fiskum et al., 2003Go; Baloyannis et al., 2004Go). Albeit the importance of inward-rectifier K+ channels relative to other types of K+ channel for the control of neuronal excitability is unclear, their widespread expression in the brain (Morishige et al., 1993Go; Falk et al., 1995Go; Horio et al., 1996Go; Karschin et al., 1996Go) raises the possibility of an important role for them in the pathophysiology of these diseases.

Acknowledgements

We thank Drs. Lily Jan and Yoshihisa Kurachi for cDNA clones of IRK1, MB-IRK2, and MB-IRK3. We also thank Dr. Diomedes Logothetis for sharing data before publication. We also thank Zac Black-wood, Cory Rahn, Tong Shen, and Tam To for technical assistance.

Footnotes

This work was supported by an award from the American Heart Association.

ABBREVIATIONS: FCCP, carbonyl cyanide p-trifluoromethoxyphenylhydrazone, PIP2, phosphatidylinositol 4,5-bisphosphate; PIPES, 1,4-piperazinediethanesulfonic acid.

Address correspondence to: Dr. Anthony Collins, Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, OR 97331-3507. E-mail: tony.collins{at}oregonstate.edu

References

Aronis A, Komarnitsky R, Shilo S, and Tirosh O (2002) Membrane depolarization of isolated rat liver mitochondria attenuates permeability transition pore opening and oxidant production. Antioxid Redox Signal 4: 647-654.[CrossRef][Medline]

Baloyannis SJ, Costa V, and Michmizos D (2004) Mitochondrial alterations in Alzheimer's disease. Am J Alzheimers Dis Other Demen 19: 89-93.[Abstract/Free Full Text]

Beuckelmann DJ, Nabauer M, and Erdmann E (1993) Alterations of K+ currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res 73: 379-385.[Abstract/Free Full Text]

Collins A and Larson M (2005) Regulation of inward rectifier K+ channels by shift of intracellular pH dependence. J Cell Physiol 202: 76-86.[CrossRef][Medline]

Collins A and Larson MK (2002) Differential sensitivity of inward rectifier K+ channels to metabolic inhibitors. J Biol Chem 277: 35815-35818.[Abstract/Free Full Text]

Doble A (1999) The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 81: 163-221.[CrossRef][Medline]

Du X, Zhang H, Lopes C, Mirshahi T, Rohacs T, and Logothetis DE (2004) Characteristic interactions with phosphatidylinositol 4,5-bisphosphate determine regulation of kir channels by diverse modulators. J Biol Chem 279: 37271-37281.[Abstract/Free Full Text]

Falk T, Meyerhof W, Corrette BJ, Schafer J, Bauer CK, Schwarz JR, and Richter D (1995) Cloning, functional expression and mRNA distribution of an inwardly rectifying potassium channel protein. FEBS Lett 367: 127-131.[CrossRef][Medline]

Fiskum G, Starkov A, Polster BM, and Chinopoulos C (2003) Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson's disease. Ann NY Acad Sci 991: 111-119.[Abstract/Free Full Text]

Guerrieri F, Lorusso M, Pansini A, Ferrarese V, and Papa S (1976) On the mechanism of action of oligomycin and acidic uncouplers on proton translocation and energy transfer in "sonic" submitochondrial particles. J Bioenerg Biomembr 8: 131-142.[CrossRef][Medline]

Han W, Chartier D, Li D, and Nattel S (2001) Ionic remodeling of cardiac Purkinje cells by congestive heart failure. Circulation 104: 2095-2100.[Abstract/Free Full Text]

Heytler PG and Prichard WW (1962) A new class of uncoupling agents—carbonyl cyanide phenylhydrazones. Biochem Biophys Res Commun 7: 272-275.[CrossRef][Medline]

Hilgemann D (1995) The giant membrane patch, in Single-Channel Recording (Sakmann B and Neher E eds) pp 307-327, Plenum Press, New York.

Hilgemann DW and Ball R (1996) Regulation of cardiac Na+, Ca2+ exchange and KATP potassium channels by PIP2. Science (Wash DC) 273: 956-959.[Abstract]

Ho K, Nichols CG, Lederer WJ, Lytton J, Vassilev PM, Kanazirska MV, and Hebert SC (1993) Cloning and expression of an inwardly rectifying ATP-regulated potassium channel. Nature (Lond) 362: 31-38.[CrossRef][Medline]

Horio Y, Morishige K, Takahashi N, and Kurachi Y (1996) Differential distribution of classical inwardly rectifying potassium channel mRNAs in the brain: comparison of IRK2 with IRK1 and IRK3. FEBS Lett 379: 239-243.[CrossRef][Medline]

Huang CL, Feng S, and Hilgemann DW (1998) Direct activation of inward rectifier potassium channels by PIP2 and its stabilization by Gbetagamma. Nature (Lond) 391: 803806.

Janse MJ (2004) Electrophysiological changes in heart failure and their relationship to arrhythmogenesis. Cardiovasc Res 61: 208-217.[Abstract/Free Full Text]

Kaab S, Nuss HB, Chiamvimonvat N, O'Rourke B, Pak PH, Kass DA, Marban E, and Tomaselli GF (1996) Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ Res 78: 262-273.[Abstract/Free Full Text]

Karschin C, Dissmann E, Stuhmer W, and Karschin A (1996) IRK1-3 and GIRK1-4 inwardly rectifying K+ channel mRNAs are differentially expressed in the adult rat brain. J Neurosci 16: 3559-3570.[Abstract/Free Full Text]

Kubo Y, Baldwin TJ, Jan YN, and Jan LY (1993) Primary structure and functional expression of a mouse inward rectifier potassium channel. Nature (Lond) 362: 127-133.[CrossRef][Medline]

Kuo A, Gulbis JM, Antcliff JF, Rahman T, Lowe ED, Zimmer J, Cuthbertson J, Ashcroft FM, Ezaki T, and Doyle DA (2003) Crystal structure of the potassium channel KirBac1.1 in the closed state. Science (Wash DC) 300: 1922-1926.[Abstract/Free Full Text]

Kurachi Y and Takahashi N (1996) Molecular and functional heterogeneity of inward rectifier potassium channels in brain and heart. J Card Fail 2: S59-S62.[CrossRef][Medline]

Liman ER, Tytgat J, and Hess P (1992) Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs. Neuron 9: 861-871.[CrossRef][Medline]

Lodge NJ and Normandin DE (1997) Alterations in Ito1, IKr and Ik1 density in the BIO TO-2 strain of syrian myopathic hamsters. J Mol Cell Cardiol 29: 3211-3221.[CrossRef][Medline]

Lopes CM, Zhang H, Rohacs T, Jin T, Yang J, and Logothetis DE (2002) Alterations in conserved Kir channel-PIP2 interactions underlie channelopathies. Neuron 34: 933-944.[CrossRef][Medline]

Luo Y, Bond JD, and Ingram VM (1997) Compromised mitochondrial function leads to increased cytosolic calcium and to activation of MAP kinases. Proc Natl Acad Sci USA 94: 9705-9710.[Abstract/Free Full Text]

Marin-Garcia J, Goldenthal MJ, and Moe GW (2001) Mitochondrial pathology in cardiac failure. Cardiovasc Res 49: 17-26.[Free Full Text]

Morishige K, Takahashi N, Findlay I, Koyama H, Zanelli JS, Peterson C, Jenkins NA, Copeland NG, Mori N, and Kurachi Y (1993) Molecular cloning, functional expression and localization of an inward rectifier potassium channel in the mouse brain. FEBS Lett 336: 375-380.[CrossRef][Medline]

Patel MN (2002) Oxidative stress, mitochondrial dysfunction and epilepsy. Free Radic Res 36: 1139-1146.[CrossRef][Medline]

Pogwizd SM, Schlotthauer K, Li L, Yuan W, and Bers DM (2001) Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifier potassium current and residual beta-adrenergic responsiveness. Circ Res 88: 1159-1167.[Abstract/Free Full Text]

Preisig Muller R, Schlichthorl G, Goerge T, Heinen S, Bruggemann A, Rajan S, Derst C, Veh RW, and Daut J (2002) Heteromerization of Kir2.x potassium channels contributes to the phenotype of Andersen's syndrome. Proc Natl Acad Sci USA 99: 7774-7779.[Abstract/Free Full Text]

Rohacs T, Chen J, Prestwich GD, and Logothetis DE (1999) Distinct specificities of inwardly rectifying K+ channels for phosphoinositides. J Biol Chem 274: 36065-36072.[Abstract/Free Full Text]

Rohacs T, Lopes C, Mirshahi T, Jin T, Zhang H, and Logothetis DE (2002) Assaying phosphatidylinositol bisphosphate regulation of potassium channels. Methods Enzymol 345: 71-92.[CrossRef][Medline]

Sadek HA, Nulton-Persson AC, Szweda PA, and Szweda LI (2003) Cardiac ischemia/reperfusion, aging and redox-dependent alterations in mitochondrial function. Arch Biochem Biophys 420: 201-208.[CrossRef][Medline]

Sims NR and Anderson MF (2002) Mitochondrial contributions to tissue damage in stroke. Neurochem Int 40: 511-526.[CrossRef][Medline]

Takahashi N, Morishige K, Jahangir A, Yamada M, Findlay I, Koyama H, and Kurachi Y (1994) Molecular cloning and functional expression of cDNA encoding a second class of inward rectifier potassium channels in the mouse brain. J Biol Chem 269: 23274-23279.[Abstract/Free Full Text]

Wang Z, Yue L, White M, Pelletier G, and Nattel S (1998) Differential distribution of inward rectifier potassium channel transcripts in human atrium versus ventricle. Circulation 98: 2422-2428.[Abstract/Free Full Text]

Zaritsky JJ, Redell JB, Tempel BL, and Schwarz TL (2001) The consequences of disrupting cardiac inwardly rectifying K+ current (IK1) as revealed by the targeted deletion of the murine Kir2.1 and Kir2.2 genes. J Physiol 533: 697-710.[Abstract/Free Full Text]

Zobel C, Cho HC, Nguyen TT, Pekhletski R, Diaz RJ, Wilson GJ, and Backx PH (2003) Molecular dissection of the inward rectifier potassium current (IK1) in rabbit cardiomyocytes: evidence for heteromeric co-assembly of Kir2.1 and Kir2.2. J Physiol 550: 365-372.[Abstract/Free Full Text]





This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.008292v1
67/4/1214    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Collins, A.
Right arrow Articles by Larson, M. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Collins, A.
Right arrow Articles by Larson, M. K.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics